-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background : Various clinical factors affecting serum insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) levels have not been fully described
.
.
Objectives : We asked whether BMI, contraceptives (CDs) and hormone replacement therapy (HRT) have a potential impact on the interpretation of the new age-, sex- and puberty-adjusted reference ranges for serum levels of IGF-I and IGFBP-3
.
.
Purpose
DESIGN AND SETTING : Subject primary participants were drawn from two population-based cohort studies: the 'LIFE Child' study and the 'LIFE Adult' study in children and adolescents
.
Participants: 3 months to 81 years
DESIGN AND SETTING : Subject primary participants were drawn from two population-based cohort studies: the 'LIFE Child' study and the 'LIFE Adult' study in children and adolescents
Main outcome measures : Association between IGF-I or IGFBP-3, measured with a novel electrochemiluminescence immunoassay, predictors BMI and CDs estimated using hierarchical linear models
Results : IGF-I had good agreement [concordance correlation coefficient = 0.
Table 1 Age distribution of non-obese girls (BMI ± 1.
Table 2 Oral and parenteral combination of estrogen-progestin-based CDs (EpCDs) or progestin-based CDs (PCDS) and estrogen- or estrogen-based hormone replacement therapy (eHRT/eHRT) ) on insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in adult females (≥19 years of age)
.
Beta estimates and corresponding 95% confidence intervals are given
Table 2 Oral and parenteral combination of estrogen-progestin-based CDs (EpCDs) or progestin-based CDs (PCDS) and estrogen- or estrogen-based hormone replacement therapy (eHRT/eHRT) ) on insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in adult females (≥19 years of age)
Table 3 Mean and standard deviation (SD) values for IGF-I and IGFBP-3 and corresponding SDS values for ECLIA and CLIA analyses
.
The median, range, mean and SD values of the difference between ECLIA and CLIA are also given
Table 3 Mean and standard deviation (SD) values for IGF-I and IGFBP-3 and corresponding SDS values for ECLIA and CLIA analyses
Conclusions: BMI and CD must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements
.
.
Original source:
Original source:Hörenz C, Vogel M, Wirkner K, et al.
Hörenz C, Vogel M, Wirkner K, et al.
BMI and contraceptives affect new age-, sex-, and puberty-adjusted IGF-I and IGFBP-3 reference ranges across life span.
J Clin Endocrinol Metab 2022 Mar 16 Comment on this